Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657254 · ClinicalTrials.gov registry record · Phase 2
Extension Program for Bay 43-9006
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00657254: Completed Phase 2 study, sponsored by Bayer.
NCT00657254 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00657254, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The study was designed to allow for the continuation of treatment with Sorafenib as a single agent to those patients who participated in a previous Sorafenib study that had reached its designated end-date and who were, in the opinion of the Investigator and the Sponsor, still benefiting from treatment.
Interventions
- DRUG Nexavar (Sorafenib, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2002-12 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
What the finished NCT00657254 record still lists
NCT00657254 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Nexavar (Sorafenib, BAY43-9006) is the first listed.
NCT00657254 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00657254 about?
NCT00657254 is a clinical study titled "Extension Program for Bay 43-9006". The study was designed to allow for the continuation of treatment with Sorafenib as a single agent to those patients who participated in a previous Sorafenib study that had reached its designated end-date and who were, in the opinion of the Investigator and the Sponsor, still benefiting from treatme...
What is the current status of trial NCT00657254?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2002-12. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00657254?
The interventions under investigation include: Nexavar (Sorafenib, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00657254?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00657254's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia